P53 apoptosis mediator PERP: Localization, function and caspase activation in uveal melanoma

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 1995-2007

  Davies, Lyndsay ^a   Gray, Donna ^a   Spiller, Dave ^a   White, Mike R H ^a   Damato, Bertil ^b   Grierson, Ian ^a   Paraoan, Luminita ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Caspase; Green fluorescent protein; P53; PERP; Transfection; Uveal melanoma

Indexed keywords

CASPASE; MEMBRANE PROTEIN; PERP PROTEIN, HUMAN; PRIMER DNA;

APOPTOSIS; ARTICLE; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; MELANOMA; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UVEA TUMOR; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASES; DNA PRIMERS; ENZYME ACTIVATION; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; MEMBRANE PROTEINS; POLYMERASE CHAIN REACTION; UVEAL NEOPLASMS;

EID: 72949116365     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00590.x     Document Type: Article

References (65)

1. Hengartner MO. The biochemistry of apoptosis. Nature. 2000 407 : 770 776.
2. Benchimol S. p53-dependent pathways of apoptosis. Cell Death Differ. 2001 8 : 1049 1051.
3. Haupt S, Berger M, Goldberg Z, et al. Apoptosis - the p53 network. J Cell Sci. 2003 116 : 4077 4085.
4. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007 14 : 3 9.
5. Sherr CJ. Principles of tumor suppression. Cell. 2004 116 : 235 246.
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000 408 : 307 310.
7. Deng C, Zhang P, Harper JW, et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995 82 : 675 684.
8. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 75 : 817 825.
9. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997 1 : 3 11.
10. Attardi LD, Reczek EE, Cosmas C, et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 2000 14 : 704 718.
11. Chao C, Saito S, Kang J, et al. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 2000 19 : 4967 4975.
12. Ihrie RA, Reczek E, Horner JS, et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol. 2003 13 : 1985 1990.
13. Nowak M, Koster C, Hammerschmidt M. Perp is required for tissue-specific cell survival during zebrafish develop-ment. Cell Death Differ. 2005 12 : 52 64.
14. Paraoan L, Gray D, Hiscott P, et al. Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: downregulation is associated with aggressive type. Exp Eye Res. 2006 83 : 911 919.
15. Egan KM, Seddon JM, Glynn RJ, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988 32 : 239 251.
16. Albert DM. The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II. Am J Ophthalmol. 1997 123 : 729 741.
17. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin. 2006 46 : 133 149.
18. Damato B. Developments in the management of uveal melanoma. Clin Exp Ophthalmol. 2004 32 : 639 647.
19. Soulieres D, Rousseau A, Tardif M, et al. The radiosensitivity of uveal melanoma cells and the cell survival curve. Graefes Arch Clin Exp Ophthalmol. 1995 233 : 85 9.
20. Sun Y, Tran BN, Worley LA, et al. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci. 2005 46 : 1561 1564.
21. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 1999 9 : 575 581.
22. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene. 2002 21 : 8786 8803.
23. Lewanski CR, Gullick WJ. Radiotherapy and cellular signalling. Lancet Oncol. 2001 2 : 366 370.
24. Wesselborg S, Engels IH, Rossmann E, et al. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood. 1999 93 : 3053 3063.
25. Brantley MA Jr., Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000 157 : 1795 1801.
26. Chana JS, Wilson GD, Cree IA, et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999 83 : 110 114.
27. Kishore K, Ghazvini S, Char DH, et al. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol. 1996 121 : 561 567.
28. Hildebrandt T, Preiherr J, Tarbe N, et al. Identification of THW, a putative new tumor suppressor gene. Anticancer Res. 2000 20 : 2801 2809.
29. Devilee P, van VM, van SP, et al. Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene. 1991 6 : 1705 1711.
30. Srikantan V, Sesterhenn IA, Davis L, et al. Allelic loss on chromosome 6Q in primary prostate cancer. Int J Cancer. 1999 84 : 331 335.
31. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science. 1990 247 : 568 571.
32. Hildebrandt T, van Dijk MC, van Muijen GN, et al. Loss of heterozygosity of gene THW is frequently found in melanoma metastases. Anticancer Res. 2001 21 : 1071 1080.
33. Kan-Mitchell J, Mitchell MS, Rao N, et al. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci. 1989 30 : 829 834.
34. de Waard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995 62 : 155 161.
35. Verbik DJ, Murray TG, Tran JM, et al. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer. 1997 73 : 470 478.
36. Paraoan L, White MR, Spiller DG, et al. Precursor cystatin C in cultured retinal pigment epithelium cells: evidence for processing through the secretory pathway. Mol Membr Biol. 2001 18 : 229 236.
37. Paraoan L, Grierson I, Maden BE. Fate of cystatin C lacking the leader sequence in RPE cells. Exp Eye Res. 2003 76 : 753 756.
38. Tusnady GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics. 2001 17 : 849 850.
39. Hofmann K, Stoffel W. TMbase-a database of membrane spanning proteins segments. Biol Chem Hoppe Seyler. 1993 374 : 166.
40. McColl KS, He H, Zhong H, et al. Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bc1-2 regulated caspase activation. Mol Cell Endocrinol. 1998 139 : 229 238.
41. Ding HF, Lin YL, McGill G, et al. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem. 2000 275 : 38905 38911.
42. Medema JP, Scaffidi C, Kischkel FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997 16 : 2794 2804.
43. Reczek EE, Flores ER, Tsay AS, et al. Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res. 2003 1 : 1048 1057.
44. Cobbold C, Monaco AP, Sivaprasadarao A, et al. Aberrant trafficking of transmembrane proteins in human disease. Trends Cell Biol. 2003 13 : 639 647.
45. Lopez-Velasco R, Morilla-Grasa A, Saornil-Alvarez MA, et al. Efficacy of five human melanocytic cell lines in experimental rabbit choroidal melanoma. Melanoma Res. 2005 15 : 29 37.
46. Marshall JC, Caissie AL, Callejo SA, et al. Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential. Pathobiology. 2004 71 : 241 245.
47. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997 104 : 777 780.
48. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998 94 : 491 501.
49. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998 94 : 481 490.
50. Martin DA, Siegel RM, Zheng L, et al. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem. 1998 273 : 4345 4349.
51. Muzio M, Stockwell BR, Stennicke HR, et al. An induced proximity model for caspase-8 activation. J Biol Chem. 1998 273 : 2926 2930.
52. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998 281 : 1305 1308.
53. Bennett M, Macdonald K, Chan SW, et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science. 1998 282 : 290 293.
54. Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997 99 : 403 413.
55. Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol. 1995 15 : 3032 3040.
56. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997 17 : 141 143.
57. Boldin MP, Varfolomeev EE, Pancer Z, et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem. 1995 270 : 7795 7798.
58. Chinnaiyan AM, O'Rourke K, Tewari M, et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 1995 81 : 505 512.
59. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD- homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996 85 : 817 827.
60. MacFarlane M, Cain K, Sun XM, et al. Processing/activation of at least four interleukin-1beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells. J Cell Biol. 1997 137 : 469 479.
61. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997 326 : 1 16.
62. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999 68 : 383 424.
63. Ziangirova GG, Likhvantseva VG, Ukhov I, et al. Key role of apoptosis in progressing uveal melanoma. Izv Akad Nauk Ser Biol. 2003 5 : 527 533. Translated in Biology Bulletin. 2003 30 : 436 441.
64. Iolascon A, Borriello A, Giordani L, et al. Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet. 2003 146 : 41 7.
65. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med. 2001 79 : 428 436.